Eli Lilly's $7 billion deal for Kelonia Therapeutics on Monday was just the latest example | Despite the recent “feeding frenzy,” Pitchbook’s Ben Zercher told Fierce he expects in vivo CAR-T dealmaking to slow due to a shortage of viable acquisition targets.